Contra is a highly potent supplement which helps to increase natural testosterone production while also inhibiting and correctly balancing cortisol levels to maximize your bodies anabolic state. Contra also contains a powerful aromatase inhibitor to prevent any unwanted estrogenic side effects while helping to maintain a lean physique.
Myoblox is a supplement which helps control estrogen and cortisol while boosting testosterone. If you're looking to support Contra with other supplements you may want to stack Contra with Multi, a whole body wellness Multivitamin from MyoBlox. If you're looking for some added energy and pumps during workouts you may want to checkout Loco, MyoBlox's pre-workout or Blo, the brands Pump Supplement.
Begin by takine one dose (1 Capsule) in the morning with your first meal. Wait approximately 8-12 hours, consume second dose (1 Capsule) with meal. Due to potency do not use this product longer than 8 weeks followed by a subsequent 4 week break. Do not exceed 2 capsules in any 24 hour period.
Serving Size: 2 Capsules
Servings Per Container: 28
Contra (2 Capsules) 1150mg
Anti-Cortisol Matrix 600mg
KSM-66 Ashwagandha Root Extract (Standardized to >5% Withanolides)
Pro-Physique Matrix 540mg
3,3'-Diindolymethane, Androsta-3,5,diene-7,17-dione, N-Cuomaroyldopamine, BLOX Micro Peptide Technology (Yielding Natural Occuring Fibroblast Growth Factors, Folistatin)
Absorption Matrix 10mg
Piperine Alkaloids (98%)
*Daily Values Not Established
Other Ingredients: Silicon DIoxide, Rice Flour, Gelatin.
Do not consume more than 2 capsules in a 24 hour period. Store in a cool dry place.
Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med. 2014;20(12):901–908. doi:10.1089/acm.2014.0177
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270108/
Rajoria S, Suriano R, Parmar PS, et al. 3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011;21(3):299–304. doi:10.1089/thy.2010.0245
